Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Mauer

Showing results (121-130 of 146) with videos related to

Pageof 15
Sort By:
Diabetes|March 2, 2018
Urinary IgG4 and Smad1 Are Specific Biomarkers for Renal Structural and Functional Changes in Early Stages of Diabetic NephropathyToshio Doi, Tatsumi Moriya, Yui Fujita, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 12, 2020
Performance of Indexed and Nonindexed Estimated GFRSilvia Titan, Shiyuan Miao, Hocine Tighiouart, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 2, 2011
Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiationDavid G Warnock, Alberto Ortiz, Michael Mauer, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 5, 2015
Urinary monocyte chemoattractant protein-1 and hepcidin and early diabetic nephropathy lesions in type 1 diabetes mellitusGudeta D Fufaa, E Jennifer Weil, Robert G Nelson, et al.
Molecular Genetics and Metabolism|December 8, 2022
Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension studyPatrick B Deegan, Ozlem Goker-Alpan, Tarekegn Geberhiwot, et al.
Molecular Genetics and Metabolism|May 26, 2023
Global reach of over 20 years of experience in the patient-centered Fabry Registry: Advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry communityChristoph Wanner, Alberto Ortiz, William R Wilcox, et al.
Journal of Medical Genetics|March 20, 2016
Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry RegistryAlberto Ortiz, Ademola Abiose, Daniel G Bichet, et al.
Plos One|May 9, 2015
Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trialFrits A Wijburg, Bernard Bénichou, Daniel G Bichet, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 10, 2020
A New Panel-Estimated GFR, Including β<sub>2</sub>-Microglobulin and β-Trace Protein and Not Including Race, Developed in a Diverse PopulationLesley A Inker, Sara J Couture, Hocine Tighiouart, et al.
Diabetes Care|July 13, 2013
Albuminuria according to status of autoimmunity and insulin sensitivity among youth with type 1 and type 2 diabetesAmy K Mottl, Abigail Lauer, Dana Dabelea, et al.
Pageof 15

Showing results (121-130 of 146) with videos related to

Sort By:
Pageof 15
Diabetes|March 2, 2018
Urinary IgG4 and Smad1 Are Specific Biomarkers for Renal Structural and Functional Changes in Early Stages of Diabetic NephropathyToshio Doi, Tatsumi Moriya, Yui Fujita, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 12, 2020
Performance of Indexed and Nonindexed Estimated GFRSilvia Titan, Shiyuan Miao, Hocine Tighiouart, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 2, 2011
Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiationDavid G Warnock, Alberto Ortiz, Michael Mauer, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 5, 2015
Urinary monocyte chemoattractant protein-1 and hepcidin and early diabetic nephropathy lesions in type 1 diabetes mellitusGudeta D Fufaa, E Jennifer Weil, Robert G Nelson, et al.
Molecular Genetics and Metabolism|December 8, 2022
Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension studyPatrick B Deegan, Ozlem Goker-Alpan, Tarekegn Geberhiwot, et al.
Molecular Genetics and Metabolism|May 26, 2023
Global reach of over 20 years of experience in the patient-centered Fabry Registry: Advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry communityChristoph Wanner, Alberto Ortiz, William R Wilcox, et al.
Journal of Medical Genetics|March 20, 2016
Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry RegistryAlberto Ortiz, Ademola Abiose, Daniel G Bichet, et al.
Plos One|May 9, 2015
Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trialFrits A Wijburg, Bernard Bénichou, Daniel G Bichet, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 10, 2020
A New Panel-Estimated GFR, Including β<sub>2</sub>-Microglobulin and β-Trace Protein and Not Including Race, Developed in a Diverse PopulationLesley A Inker, Sara J Couture, Hocine Tighiouart, et al.
Diabetes Care|July 13, 2013
Albuminuria according to status of autoimmunity and insulin sensitivity among youth with type 1 and type 2 diabetesAmy K Mottl, Abigail Lauer, Dana Dabelea, et al.
Pageof 15